TMCnet News
RAPT Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Virtual Scientific ProgramSOUTH SAN FRANCISCO, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the presentation of a Trials in Progress poster for the ongoing seamless Phase 1/2 clinical trial of FLX475, a small molecule CCR4 antagonist in development for multiple tumor types. The poster was presented at the American Society of Clinical Oncology (ASCO) 2020. The poster presentation detailed previously reported initial Phase 1 healthy volunteer data for FLX475 that demonstrated excellent safety, pharmacokinetics (PK) and target engagement. FLX475 is designed to block regulatory T cells from migrating to tumor sites, where they suppress immune system responses to cancer cells, without depleting regulatory T cells in the rest of the body nor immune cells required for an anti-tumor response. A robust pharmacodynamic (PD) assay measuring receptor occupancy on circulating regulatory T cells demonstrated that FLX475 achieved exposure levels over the targeted 75%, predicting maximal inhibition of regulatory T cell recruitment into tumors via CCR4 signaling. In addition, levels of FLX475 increased in a dose-proportional manner, with a strong PK/PD correlation observed between drug levels and receptor occupancy. Building on these data, RAPT initiated a seamless Phase 1/2 study of FLX475. The Phase 1 portion of the trial was a standard dose escalation study in patients with many types of cancer, and the Phase 2 portion is evaluating FLX475 both as monotherapy and in combination with a checkpoint inhibitor in patients with “charged” tumors, which are tumors that express high levels of CCR4 ligands (CCL17 and CCL22), and have a high presence of regulatory T cells and CD8+ effector T cells. RAPT is currently enrolling the Phase 2 portion of the trial in patients with charged tumors, including non-small cell lung cancer, triple negative breast cancer, head and neck squamous cell carcinoma, cervical cancer as well as EBV-positive nasopharyngeal cancer and lymphomas. “We are pleased with our continued progress inclinical evaluation of FLX475 and remain encouraged by our early observations,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics. “The previously reported checkpoint inhibitor-refractory patient with non-small cell lung cancer with a confirmed partial response in the Phase 1 part of this study continues to respond to FLX475 plus Keytruda, and is approaching the 1-year mark of study treatment. Our sites in the U.S., Australia and Asia continue to enroll patients and we remain on track to report results for both the Phase 1 and initial Phase 2 expansion cohorts in the second half of 2020.” The poster presented at ASCO can be viewed on the RAPT website under the Events and Presentation tab of the Investor Relations section here. About FLX475 About RAPT Therapeutics, Inc. Forward-Looking Statements RAPT Media Contact: RAPT Investor Contact: |